The pathogenesis and treatment of obsessive-compulsive disorder

Clinical Neuropharmacology

Volumn 19, Issue 2, 1996, Pages 129-147

  Dolberg, O T ^a   Iancu, I ^a   Sasson, Y ^a   Zohar, J ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

Behavioral therapy; Obsessive compulsive disorder; Serotonin

Indexed keywords

6 CHLORO 2 (1 PIPERAZINYL)PYRAZINE; ALPRAZOLAM; ANXIOLYTIC AGENT; BUSPIRONE; CLOMIPRAMINE; CLONAZEPAM; CLORGYLINE; DESIPRAMINE; DIPHENHYDRAMINE; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; IPSAPIRONE; MECOPROP; NEUROLEPTIC AGENT; PAROXETINE; PHENELZINE; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRYPTOPHAN;

ANTICHOLINERGIC EFFECT; BEHAVIOR THERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; ELECTROCONVULSIVE THERAPY; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAINTENANCE THERAPY; NAUSEA; NEUROSURGERY; OBSESSION; ORAL DRUG ADMINISTRATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SLEEP DISORDER;

EID: 0029877198     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199619020-00002     Document Type: Review

References (112)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders-DSM-IV. 4th ed. Washington, DC: American Psychiatric Association, 1994.
2. Salzman L, Thaler FH. Obsessive-compulsive disorder: a review of the literature. Am J Psychiatry 1981;138:286-96.
3. Lopez-Ibor AJ. Intravenous perfusion of monochlorimipramine. Techniques and results. Proceedings of the International College of CINP. April 1968 (Int. Congress Series, 180, 519). Teragone, The Netherlands: Excerpta Medica, 1969.
4. Rudin E. Ein beitrag zur frage der zwangskrunkheit insebesondere ihrere hereditaren beziehungen. Arch Psychiatr Nervenkr 1953;191:14-54.
5. Robins LN, Helzer JE, Weissman MM, et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984;41:949-58.
6. Myers JK, Weissman MM, Tischler GL, et al. Six month prevalence of psychiatric disorders in three communities. Arch Gen Psychiatry 1984;41:959-67.
7. Bland RC, Newman SC, Orn H. Period prevalence of psychiatric disorders in Edmonton. Acta Psychiatr Scand 1988;338:33s-42s.
8. Bland RC, Newman SC, Orn H. Lifetime prevalence of psychiatric disorders in Edmonton. Acta Psychiatr Scand 1988;338:24s-32s.
9. Weissman MM, Bland RC, Canino GJ, et al. The cross national epidemiology of obsessive compulsive disorder. The cross national collaborative group. J Clin Psychiatry 1994;55:5s-10s.
10. Black A. The natural history of obsessional neurosis. In: Beech HR, ed. Obsessional states. London: Methuen, 1974:1-23.
11. Rasmussen SA, Eisen JL. The epidemiology and clinical features of obsessive compulsive disorder. Psychiatr Clin North Am 1992;15:743-59.
12. Rapoport JL, ed. Obsessive compulsive disorder in children and adolescents. Washington, DC: American Psychiatric Association. 1989.
13. Rasmussen SA, Eisen JL. Clinical and epidemiologic findings of significance to neuropharmacologic trials in OCD. Psychopharmacol Bull 1988;24:466-70.
14. Goodman WK. The diagnosis of OCD. Focus OCD 1993;1:2-3.
15. Rasmussen SA, Eisen JL. Phenomenology of OCD: clinical subtypes, heterogeneity and coex- istence. In: Zohar J, Insel T, Rasmussen S, eds. The psychobiology of obsessive compulsive disorder. Springer series on psychiatry. New York: Springer, 1991:13-44.
16. Kindler S, Zohar J, Zohar-Kadouch RC. Obsessive-compulsive disorder: current concepts and drug treatment. New Ethicals 1992;29:87-97.
17. World Health Organization. The ICD-10 classification of mental and behavioral disorders. Geneva: World Health Organization, 1992.
18. Stein DJ, Hollander E. The spectrum of obsessive-compulsive-related disorders. In: Hollander E, ed. Obsessive-compulsive related disorders. Washington, DC: American Psychiatric Press, 1993:241-71.
19. Freeman CPL, Hampson M. Fluoxetine as a treatment for bulimia nervosa. Int J Obs 1987;11: 171-7.
20. Rasmussen SA, Eisen JL, Pato MT. Current issues in the pharmacologic management of obsessive compulsive disorder. J Clin Psychiatry 1993;54:4s-9s.
21. Renynghe de Voxrie GV. Anafranil (G34586) in obsessive compulsive neurosis. Arch Neurol Belg 1968;68:787-92.
22. Fernandez-Cordoba E, Lopez-Ibor AJ. La monoclorimiprimina en enfermos psiquiatricos resistentes a otros tratamientos. Actas Luso Esp Neurol Psiquiatr 1967;26:119-47.
23. Ananth J, Pecknold JC, Van Den Steen N, Engelsmann F. Double blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Pros Neuropsychopharmacol 1981;5:257-62.
24. Flament MF, Rapoport JL, Berg CJ, et al. Clomipramine treatment of childhood obsessive compulsive disorder: a double-blind controlled study. Arch Gen Psychiatry 1985;42:977-83.
25. Insel TR, Murphy DL, Cohen RM, Alterman I, Kilts C, Linnoila M. Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983;40:605-12.
26. Marks IM, Stern RS, Mawson D, Cobb J, McDonald R. Clomipramine and exposure for obsessive-compulsive rituals: I. Br J Psychiatry 1980;136:1-25.
27. Montgomery SA. Clomipramine in obsessional neurosis: a placebo controlled trial. Pharm Med 1980;1:189-92.
28. Thoren P, Asberg M, Gronholm B, Jornestedt L, Traskman L. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry 1980;37: 1281-5.
29. Volavka J, Neziroglu F, Yaryura-Tobias JA. Clomipramine and imipramine in obsessive-compulsive disorder. Psychiatry Res 1985;14:85-93.
30. Zohar J, Insel T. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry 1987;22:667-87.
31. Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48:730-8.
32. Mavissakalian M, Turner SM, Michelson L, Jacob R. Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessional or antidepressant agents? Am J Psychiatry 1985;142:572-6.
33. Insel TR, Alterman I, Murphy DL. Antiobsessional and anti-depressant effects of clomipramine in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull 1982;18:115-17.
34. Murphy DL, Siever LJ, Insel TR. Therapeutic responses to tricyclic antidepressants and related drugs in non-affective disorder patient population. Prog Neuropsychopharmacol Biol Psychiatry 1985;9:3-13.
35. Montgomery SA, McIntyre A, Osterheider M, et al. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. Eur Neuropsychopharmacol 1993;3:143-52.
36. Tollefson GD, Rampey AH, Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994;51:559-67.
37. Westenberg HGM, De Leeuw AS, Den Boer JA. Serotonin reuptake blockers in obsessive compulsive disorder: a controlled trial with fluvoxamine. Proceedings 18th CINP Congress, 1992:116, Nice.
38. Greist JH. Fluvoxamine treatment of OCD. 5th World Congress on Biological Psychiatry. June 9-14, Florence, Italy, 1991.
39. Goodman WK, Price LH, Rasmussen SA. Efficacy of fluvoxamine in obsessive-compulsive disorder: a double-blind comparison of fluvoxamine and placebo. Arch Gen Psychiatry 1989;46: 36-40.
40. Jenike MA, Hyman S, Baer L, et al. A controlled trial of fluvoxamine in obsessive-compulsive disorder. Am J Psychiatry 1990;147:1209-15.
41. Perse TL, Greist JH, Jefferson RH, Rosenfeld R, Dar R. Fluvoxaraine treatment of obsessive-compulsive disorder. Am J Psychiatry 1988;144:1543-8.
42. Mallya GK, White K, Waternaux C, Quay S. Short- and long-term treatment of OCD with fluvoxamine. Ann Clin Psychiatry 1992;4:77-80.
43. Greist J, Chouinard G, DuBoff E, et al. Long-term sertraline treatment of obsessive compulsive disorder: a 52-week double blind comparative study versus placebo. 9th World Congress of Psychiatry, Rio de Janeiro, Brazil. June 1993:20-21.
44. Chouinard G, Goodman W, Greist J, et al. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive compulsive disorder. Psychopharmacol Bull 1990;26:279-84.
45. Greist J, Chouinard G, DuBoff E, et al. Double-blind comparison of three doses of sertraline and placebo in the treatment of outpatients with obsessive compulsive disorder. 9th World Congress of Psychiatry, Rio de Janeiro, Brazil. June 1993:18-19.
46. Wheadon DE, Bushnell WD, Steiner M. A fixed dose comparison of 20, 40, or 60 mg paroxetine to placebo in the treatment of OCD. Presented at the 1993 Annual Meeting of the American College of Neuropsychopharmacology, Honolulu, HI, December 14, 1993.
47. Steiner M, Oakes R, Gergel IP, Wheadon DE. Predictors of response to paroxetine therapy in OCD. Presented at the 1994 Annual Meeting, American Psychiatric Aassociation, Philadelphia, PA, May 21-26, 1994.
48. Pato PT, Zohar-Kadouch RC, Zohar J, Murphy DL. Return of symptoms after discontinuation of clorimipramine in patients with obsessive compulsive disorder. Am J Psychiatry 1988;145: 1521-5.
49. Leonard H, Swedo S, Koby E, et al. Treatment of obsessive-compulsive disorder with clomipramine and desmethylimipramine in children and adolescents. A double-blind crossover comparison. Arch Gen Psychiatry 1989;46:1088-92.
50. Leonard H, Swedo SE, Lenane MC, et al. A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48:922-7.
51. Zohar J, Kindler S, Sasson Y, et al. A double-blind study to assess the efficacy and tolerance of paroxeline compared with clomipramine and placebo in the treatment of obsessive compulsive disorder. Presented at the Annual Meeting of the Association of European Psychiatry. September 1994.
52. Pigott TA, Pato MT, Bernstein SE. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive compulsive disorder. Behavioral and biological results. Arch Gen Psychiatry 1990;47:926-32.
53. Freeman CPL, Trimble MR, Deatin JEW, Stokes TM, Ashford JA. Fluvoxamine versus clomipramine in the treatment of OCD: a multicenter, randomized, double-blind, parallel-group comparison. J Clin Psychiatry 1994;55:301-5.
54. Tollefson G. Alprazolam in the treatment of obsessive symptoms. J Clin Psychopharmacol 1985;5:39-42.
55. Hewlett WA, Vinogradov S, Argas WS. Clonazepam treatment of obsessions and compulsions. J Clin Psychiatry 1990;51:158-61.
56. Hewlett WA, Vinogradov S, Agras WS. Clomipramine, clonazepam and clonidine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1992;12:420-30.
57. Insel TR, Murphy DL, Cohen RM. Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983;40:605-12.
58. Vallejo J, Olivares J, Marcos T, Bulbena A, Menchon JM. Clomipramine versus phenelzine in obsessive compulsive disorder: a controlled clinical trial. Br J Psychiatry 1992;161:665-70.
59. Hermesh H, Aizenberg D, Munitz H. Trazodone treatment of clomipramine-resistant obsessive-compulsive disorder. Clin Neuropharmacol 1990;13:322-8.
60. Pigott TA, L'Heureux F, Rubinstein CS, Bernstein SE, Hill JL, Murphy DL. Double-blind, placebo-controlled study of trazodone in patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992;12:156-62.
61. Pato PT, Pigott TA, Hill JL, Grover GN, Bernstein S, Murphy DL. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1991;148:127-9.
62. Jenike MA, Baer L, Buttolph L. Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder. J Clin Psychiatry 1991;52:13-4.
63. Dar R, Greist JH. Behavior therapy for obsessive-compulsive disorder. Psychiatr Clin North Am 1992;15:885-94.
64. Goodman WK, McDougle CJ, Barr LC, et al. Biological approaches to treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 1993;54s:16-26.
65. Zohar J, Zohar-Kadouch RC, Kindler S. Current concepts in the pharmacological treatment of obsessive-compulsive disorder. Drugs 1992;2:210-8.
66. McDougle CJ, Goodman WK, Leckman JF, Price LH. The psychopharmacology of obsessive-compulsive disorder. Psychiatr Clin North Am 1993;16:749-66.
67. Mellman LA, Gorman JM. Successful treatment of obsessive-compulsive disorder. Psychiatry 1992;141:596-7.
68. Maletzky B, McFarland B, Burt A. Refractory obsessive-compulsive disorder. Therapy 1994;10: 34-42.
69. Mindus P, Jenike MA. Neurosurgical treatment of malignant obsessive-compulsive disorder. Psychiatr Clin North Am 1992;15:921-38.
70. Jenike MA, Baer L, Ballantine T, et al. Cingulotomy for refractory obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48:548-55.
71. Barr LC, Goodman WK, Price LH. The serotonin hypothesis of obsessive compulsive disorder. Int Clin Psychopharmacol 1993;8:79s-82s.
72. DeVeaugh-Geiss J, Landau P, Katz R. Treatment of obsessive-compulsive disorder with clomipramine. Psychiatr Ann 1989;19:97-101.
73. Leonard HL, Swedo SE, Rapoport JL, et al. Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. Arch Gen Psychiatry 1989;46:1088-92.
74. Flament MF, Rapoport JL, Murphy DL, Lake CR, Berg CJ. Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder. Arch Gen Psychiatry 1987; 44:219-25.
75. Insel TR. Toward a neuroanatomy of obsessive-compulsive disorder. Arch Gen Psychiatry 1992; 49:739-44.
76. Stern RS, Marks IM, Wright J, Luscombe DK. Clomipramine: plasma levels, side effects and outcome in obsessive compulsive neurosis. Postgrad Med J 1980;56:134-9.
77. Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L. Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. Arch Gen Psychiatry 1980;37:1289-94.
78. Insel TR, Mueller EA, Alterman I, Linnoila M, Murphy DL. Obsessive compulsive disorder and serotonin: is there a connection? Biol Psychiatry 1985;20:1174-88.
79. Lydiard RB, Ballenger JC, Ellinwood E, et al. CSF monoamine metabolites in obsessive-compulsive disorder. Proceedings 143rd annual meeting of the American Psychiatric Association. May 1990, New York.
80. Weizman A, Carmi M, Hermesh H, et al. High affinity imipramine binding and serotonin uptake in platelets of eight adolescent and ten adult obsessive-compulsive patients. Am J Psychiatry 1986;143:335-9.
81. Marazziti D, Hollander E, Lensi P, Ravagli S, Cassano GB. Peripheral markers of serotonin and dopamine function in obsessive-compulsive disorder. Psychiatr Res 1992;42:41-51.
82. Bastani B, Arora RC, Meltzer HY. Serotonin uptake and imipramine binding in the blood platelets of obsessive-compulsive disorder patients. Biol Psychiatry 1991;30:131-9.
83. Vitiello B, Shimon H, Behar D, Stoff D, Bridger WH, Friedman E. Platelet imipramine binding and serotonin uptake in obsessive-compulsive patients. Acta Psychiatr Scand 1991;84:29-32.
84. 3H-imipramine binding sites in obsessive-compulsive behavior. Biol Psychiatry 1991;30:467-74.
85. Barr LC, Goodman WK, Price LH, McDougle CJ, Charney DS. The serotonin hypothesis of obsessive compulsive disorder. Implications of pharmacologic challenge studies. J Clin Psychiatry 1992;4:17s-28s.
86. Sandyk R. Tryptophan in neuropsychiatric disorders: a review, Int J Neurosci 1992;67:127-44.
87. Charney DS, Goodman WK, Price LH, Woods SW, Rasmussen SA, Heninger GR. Serotonin function in obsessive-compulsive disorder: a comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry 1988;45:177-85.
88. Barr LC, Goodman WK, McDougle CJ, et al. Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry 1994; 51:309-17.
89. Zohar J, Klein EM, Mueller A, Insel TR, Uhde TW, Murphy DL. 5HT, obsessive-compulsive disorder and anxiety. Proceedings of the American Psychiatric Association. Chicago 1987:175.
90. Hewlett WA, Vinogradov S, Martin K, Berman S, Csernansky JG. Fenfluramine stimulation of prolactin in obsessive compulsive disorder. Psychiatry Res 1992;42:81-92.
91. Lucey JV, Butcher G, Clare AW, Dinan TG. The anterior pituitary responds normally to protirelin in obsessive-compulsive disorder: evidence to support a neuroendocrine serotonergic deficit. Acta Psychiatr Scand 1993;87:384-8.
92. Zohar J, Insel TR, Zohar-Kadouch RC, Mueller EA, Murphy DL. Serotonergic role in obsessive-compulsive disorder. In: Progress in catecholamine research, Part C: clinical aspects. New York: Alan R. Liss, 1988:385-91.
93. Hamik A, Peroutka S. 1-m-Chlorophenyl piperazine (mCPP) interaction with neurotransmitter receptors in human brain. Biol Psychiatry 1989;25:569-75.
94. Hollander E, DeCaria CM, Nitescu A, et al. Serotonergic function in obsessive-compulsive disorder: behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry 1992;49:21-8.
95. Pigott TA, Grady TA, Bernstein SE, et al. A comparison of oral and IV m-CPP in patients with OCD. Biol Psychiatry 1992;31:173A.
96. Pigott TA, Zohar J, Hill JL, et al. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder. Biol Psychiatry 1991;29:418-26.
97. Pigott TA, Hill JL, Grady TA, et al. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP. Biol Psychiatry 1993;33:3-14.
98. Zohar J, Insel TR, Zohar-Kadouch RC, Hill JL, Murphy DL. Serotonergic responsivity in obsessive-compulsive disorder: effects of chronic clomipramine treatment. Arch Gen Psychiatry 1988;45:167-72.
99. Hollander E, DeCaria CM, Gully R, et al. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chloro-phenylpiperazine in obsessive-compulsive disorder. Psychiatr Res 1991;36:161-77.
100. Lesch KP, Hoh A, Disselkamp-Tietze J, Wiesmann M, Osterheider M, Schulte HM. 5-Hydroxy-tryptamine 1A receptor responsivity in obsessive-compulsive disorder. Comparison of patients and controls. Arch Gen Psychiatry 1991;48:540-7.
101. Lesch KP, Hoh A, Schulte HM, Osterheider M, Muller T. Long-term fluoxetine treatment decreases 5-HT1A receptor responsivity in obsessive-compulsive disorder. Psychopharmacology 1991;105:415-20.
102. Zohar J, Kindler S. Serotonergic probes in obsessive compulsive disorder. Int Clin Psychopharmacol 1992;7:39s-40s.
103. Bastani B, Nash JF, Meltzer HY. Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessive-compulsive disorder. Arch Gen Psychiatry 1990;47:833-9.
104. German JM, Liebowitz MR, Fyer AJ, et al. Lactate infusions in obsessive-compulsive disorder. Am J Psychiatry 1985;142:864-6.
105. Rasmussen SA, Goodman WK, Woods SW, Heninger GR, Charney DS. Effects of yohimbine in obsessive compulsive disorder. Psychopharmacology 1987;93:308-13.
106. Gorman JM, Fyer MR, Liebowitz MR. Pharmacologic provocation of panic attacks. In: Meltzaer HY. ed. Psychopharmacology. the third generation of progress. New York: Raven Press, 1987: 985-93.
107. Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL. Serotonergic responsivity in obsessive-compulsive disorder: comparison of patients and healthy controls. Arch Gen Psychiatry 1987;44:946-51.
108. Weizman A, Zohar J, Insel TR. Biological markers in obsessive-compulsive disorder. In: Zohar J, Insel TR, Rasmussen S, eds. The psychobiology of obsessive-compulsive disorder. New York: Springer, 1991:146-61.
109. Behar D, Rapoport JL, Berg CJ. Computerized tomography and neuropsychological test measures in adolescents with obsessive-compulsive disorder. Am J Psychiatry 1984;141:363-9.
110. Rapoport J, Wise S, Lauffer M, Munitz H. Obsessive-compulsive disorder: a basal ganglia disease? In: Rapoport J, ed. Obsessive-compulsive disorder in children and adolescents. Washington, DC: APPI Press, 1988:327-44.
111. Baxter LR, Schwartz JM, Bergman KS, et al. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry 1992;49: 681-9.
112. Swedo SE, Pietrini P, Leonard HL, et al. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder: revisualization during pharmacotherapy. Arch Gen Psychiatry 1992;49:690-4.